Sanofi · SNY · FY2026 Q2 · Calendar Q3 2026
Sanofi raises 2026 outlook as Dupixent and new launches lead
Sanofi’s raised 2026 outlook and expanded long-term ambitions reflect confidence in Dupixent, newer product launches and operating leverage. Whether that growth is durable depends on execution across the pipeline and R&D transformation, while the Regeneron relationship and tougher comparisons remain important risks.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about SNY FY2026 Q2
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised full-year 2026 sales-growth guidance to around 10%, with EPS expected to grow faster than sales, and increased its 2030 ambitions for Dupixent, pharmaceutical launches and vaccines. The call also emphasized a moderate increase in R&D spending and a transformation led by the new head of R&D.
Guidance delta
Raised: full-year 2026 sales growth is now expected to be around 10%, with EPS growth expected to outpace sales.
Key takeaways
- Management attributed growth to new launches, including Ayvakit, ALTUVIIIO and Sarclisa, and continued Dupixent volume expansion.
- Dupixent’s 2030 sales ambition was raised; management also increased its ambitions for pharmaceutical launches and vaccines.
- The company plans to accelerate R&D transformation, pursue disciplined business development and deepen its presence in rare diseases and China.
- The Regeneron alliance remains an area to watch as management described rebuilding trust and potentially expanding collaboration.
Management priorities
- Launch existing medicines and vaccines in additional geographies.
- Accelerate R&D transformation and pipeline prioritization.
- Pursue disciplined M&A aligned with strategic pillars.
- Deepen presence in China and rare-disease markets; rebuild the Regeneron collaboration.
Follow SNY with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationSanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases.…
Historical context
All SNY earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +19.5% | IDEXX raises 2026 outlook as diagnostics, placements and software support growth |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | -14.0% | Axsome reports Q3 growth led by AUVELITY; pipeline advances |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +9.5% | Tempus pairs Q3 growth with new partnerships and execution risks |
| AZN AstraZeneca PLC | FY2026 Q3 · Calendar Q4 2026 | +7.3% | +7.0% | AstraZeneca pairs solid growth with pipeline investment and restructuring |
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | +14.2% | +11.1% | BrightSpring posts strong Q3 growth while maintaining guidance |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.4% | +1.4% | AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive Q3 growth |
Latest beats and misses
Who reports nextBeat on EPS
- SNYFY2026 Q3 · October 30, 2026+30.8% EPS+2.8% move
- CHDFY2026 Q3 · October 30, 2026+2.2% EPS+1.2% move
- AZNFY2026 Q3 · October 30, 2026+7.3% EPS+7.0% move
- FRTFY2026 Q3 · October 30, 2026+3.9% EPS-1.1% move
- CVXFY2026 Q3 · October 30, 2026+8.4% EPS+1.8% move
- BTSGFY2026 Q3 · October 30, 2026+14.2% EPS+11.1% move
Missed on EPS
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- DLR-PLFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLR-PKFY2026 Q3 · October 29, 2026-8.4% EPS— move
Get the SNY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-30T08:05:28.482215+00:00
- FN2 earnings calendar · 2026-09-04T01:23:15.205020+00:00
- Polygon adjusted daily market bars · 2026-11-02T17:40:45.011819+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-02T17:40:45.007552+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-02. For educational purposes only; not investment advice.